Life Science Nation Newsletter  | September 14,  2017  |  Issue 231

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Sept. 1  - Sept. 13)
Makes Strategic Investments in Personalized Health Technologies
Invests in Healthcare IT, Tech Enabled Services and Diagnostics
Seeks Medical Device, Data and Health Monitoring Opportunities
Invests in Therapeutics, Devices and HCIT for Cardiovascular Diseases, Pain, Kidney Diseases and More
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Natasha Eldridge, Director of RESI Conference Series, LSN

Life Science Nation (LSN) is proud to announce that McDermott Will & Emery will serve as a title sponsor for the inaugural RESI NYC on November 15, 2017. McDermott joins RESI NYC title sponsors WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, and Johnson and Johnson Innovation (JLABS), which provides state of the art laboratories, core research facilities, resources and connections to early stage life science innovators.

"We are proud to have been a sponsor of RESI since its inception and are particularly excited to join Wuxi AppTec and JLABS as title sponsors of the inaugural RESI in New York, a burgeoning region for life sciences," said Byron Kalogerou, founder and chair of the firm's Life Sciences Industry Group...

New at RESI Boston and RESI NYC: Academic and Tech Transfer Registration
By Lauren Schulkamp, Business Development Manager-RESI Conference Series, LSN

We are excited to welcome academic scientists and tech transfer professionals to RESI for the first time. The Redefining Early Stage Investments Conference (RESI) is now offering a special academic rate to universities, institutes, tech transfer offices, and hospitals to shine the spotlight on some of the most innovative emerging technology. If you'd like to come to RESI to network with over 300 early stage life science investors, you can get an academic registration online now. Academic registration includes the following:
  • All day access pass to 24 panels & workshops, RESI's ad hoc meeting area, Exhibit Hall and Innovation Challenge, meals, and the evening Cocktail Reception
  • Full day of networking with early stage investors and pharma external innovation staff
  • Learn from life science investors and understand their investment strategies
  • Listen to current fundraising life science CEOs describe their process in developing a fundraising strategy
  • Get to know the experts as they explain the valuation process, organizing an outbound marketing campaign, negotiating term sheets, and other post-academia commercialization topics
Click here to learn more about how to qualify...
By Michael Quigley, VP of Investor Research, LSN

Healthcare payers and healthcare providers alike stand to gain significant increases in cost efficiency as a result of the successful implementation of new technologies into their workflows and into the lives of the patients they care for and insure. As such it is no surprise that many of these groups have begun investing into early stage technologies, either through their own corporate venture vehicles or by sponsoring external venture funds.

Beyond simply providing capital, these groups represent a tremendous value-adding resource for the companies that they invest in. Based on our conversations and experience in reaching out to these groups on behalf of companies, they are almost exclusively investing with a strategic mandate, targeting technologies where they can be a customer or help drive adoption in a meaningful way. This leads to them primarily focusing on healthcare IT, tech-enabled services and, to a lesser extent, low-risk medical technologies...

At RESI Boston on Sept 26 th, the Payer & Provider Venture Funds Panel will feature 4 speakers from these funds, who will discuss the types and stages of technologies they are looking for, how they add value outside of capital, and where they see their space going in the next few years. Attendees of the session will hear from:
  • Kristi Ebong, Director of Emerging Technology, Cedars-Sinai Accelerator Powered by Techstars
  • Christiana DelloRusso, Partner, Providence Ventures
  • Michael Thomas, Director, Inova Personalized Healthcare Accelerator
  • Tom Hawes, Managing Director, Sandbox Industries